News Releases

AUSTIN, Texas , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,

AUSTIN, Texas , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,

AUSTIN, Texas , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,

AUSTIN, Texas , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic

The Agreement Will Support the Development of a Potential New Treatment Option for Multiple Myeloma AUSTIN, Texas , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM) today announced an agreement with Takeda Pharmaceutical Company Limited (Takeda) for the joint development

AUSTIN, Texas , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,

AUSTIN, Texas , June 21, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in

ASCO Posters Feature Data on MT-3724 and Evofosfamide AUSTIN, Texas , June 04, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies

AUSTIN, Texas , May 31, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics

ASCO Posters to Feature Data on MT-3724 and Evofosfamide AUSTIN, Texas , May 16, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic